---
document_datetime: 2025-12-02 05:15:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pravafenix.html
document_name: pravafenix.html
version: success
processing_time: 0.11483
conversion_datetime: 2025-12-29 22:17:33.642338
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pravafenix

[RSS](/en/individual-human-medicine.xml/66294)

##### Authorised

This medicine is authorised for use in the European Union

fenofibrate / pravastatin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pravafenix](#news-on)
- [More information on Pravafenix](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pravafenix is used in adults at high risk of heart disease whose low-density-lipoprotein (LDL) cholesterol is already being controlled with pravastatin alone or another medicine from the statin family, but who still need to improve their high-density-lipoprotein (HDL) cholesterol levels and reduce their levels of triglycerides (another type of fat) in the blood. Pravafenix is used in addition to other measures such as diet, exercise and weight reduction.

Pravafenix contains the active substances pravastatin and fenofibrate.

Expand section

Collapse section

## How is Pravafenix used?

Pravafenix can only be obtained with a prescription. It is available as capsules to be taken by mouth once a day with food, during the evening meal. Before starting treatment with Pravafenix, the doctor should first investigate all possible causes of the patient's abnormal cholesterol and triglyceride blood levels and recommend a suitable diet.

The patient's blood should be monitored regularly to see how the medicine is working. The doctor should stop treatment if an adequate response does not occur within three months.

## How does Pravafenix work?

The active substances in Pravafenix, pravastatin and fenofibrate, work in different ways and their actions have a complementary effect.

Pravastatin belongs to a group of medicines called statins. It reduces total blood cholesterol by blocking the action of the HMG-CoA reductase, an enzyme (protein) in the liver involved in the production of cholesterol. As the liver needs cholesterol to produce bile, the reduced blood cholesterol level causes the liver cells to produce receptors that draw LDL cholesterol from the blood, reducing its level even further.

Fenofibrate attaches to the peroxisome proliferator-activated receptor alpha (PPAR alpha), which is involved in breaking down fat from the diet, especially triglycerides. When the receptors are activated, the breakdown of fats is accelerated, and this helps clear the blood of cholesterol and triglycerides.

## What benefits of Pravafenix have been shown in studies?

Because pravastatin and fenofibrate have been used in clinical practice for a long time, the company presented information from the scientific literature. Additionally, a main study showed that Pravafenix is more effective than pravastatin alone in reducing blood levels of non-HDL cholesterol.

The main study involved 248 patients at high risk of heart disease who had abnormal levels of cholesterol and triglycerides in the blood. Patients were either treated with Pravafenix or pravastatin alone. After 12 weeks of treatment, non-HDL cholesterol was reduced by an average of around 14% in patients taking Pravafenix, compared with an average of around 6% in patients taking pravastatin alone.

An additional study confirmed the effectiveness of Pravafenix compared with other statin medicines given alone in patients treated by different doctors such as family doctors, cardiologists or endocrinologists.

## What are the risks associated with Pravafenix?

For the complete list of side effects and restrictions with Pravafenix, see the package leaflet.

The most common side effects with Pravafenix (which may affect up to 1 in 10 people) include abdominal distension (bloating), abdominal (belly) pain, constipation, diarrhoea, dry mouth, dyspepsia (heartburn), eructation (belching), flatulence (gas), nausea (feeling sick), abdominal discomfort, vomiting and raised blood levels of liver enzymes.

Pravafenix must not be used in patients aged less than 18 years or in patients with severe liver problems, moderate to severe kidney problems, photo allergy or phototoxic reactions (allergic reaction or skin damage due to light exposure) during treatment with fibrates or ketoprofen medicines. It must also not be used in patients with gall bladder disease, chronic or acute pancreatitis (inflammation of the pancreas) or a history of myopathy (muscle disorders) or rhabdomyolysis (breakdown of muscle fibres) following treatment with a statin or fibrate medicine. It must not be taken by women who are pregnant or breastfeeding.

## Why is Pravafenix authorised in the EU?

Data from the scientific literature and from two studies show that Pravafenix, which combines a statin and fenofibrate, is more effective than a statin alone to reduce LDL cholesterol in patients who have high levels of triglycerides and low levels of HDL cholesterol. Regarding safety, side effects with Pravafenix were considered acceptable for the patients in which it is used.

The European Medicines Agency therefore decided that Pravafenix's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pravafenix?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pravafenix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pravafenix are continuously monitored. Suspected side effects reported with Pravafenix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pravafenix

Pravafenix received a marketing authorisation valid throughout EU on 14 April 2011.

Pravafenix  : EPAR - Summary for the public

Reference Number: EMA/495148/2024

English (EN) (117.1 KB - PDF)

**First published:** 17/05/2011

**Last updated:** 17/01/2025

[View](/en/documents/overview/pravafenix-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-918)

български (BG) (148.89 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/bg/documents/overview/pravafenix-epar-summary-public_bg.pdf)

español (ES) (136.39 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/es/documents/overview/pravafenix-epar-summary-public_es.pdf)

čeština (CS) (147.99 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/cs/documents/overview/pravafenix-epar-summary-public_cs.pdf)

dansk (DA) (132.95 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/da/documents/overview/pravafenix-epar-summary-public_da.pdf)

Deutsch (DE) (127.65 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/de/documents/overview/pravafenix-epar-summary-public_de.pdf)

eesti keel (ET) (131.5 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/et/documents/overview/pravafenix-epar-summary-public_et.pdf)

ελληνικά (EL) (155.46 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/el/documents/overview/pravafenix-epar-summary-public_el.pdf)

français (FR) (125.01 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/fr/documents/overview/pravafenix-epar-summary-public_fr.pdf)

hrvatski (HR) (145.51 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/hr/documents/overview/pravafenix-epar-summary-public_hr.pdf)

italiano (IT) (134.9 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/it/documents/overview/pravafenix-epar-summary-public_it.pdf)

latviešu valoda (LV) (152.57 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/lv/documents/overview/pravafenix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (146.9 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/lt/documents/overview/pravafenix-epar-summary-public_lt.pdf)

magyar (HU) (146.93 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/hu/documents/overview/pravafenix-epar-summary-public_hu.pdf)

Malti (MT) (147.86 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/mt/documents/overview/pravafenix-epar-summary-public_mt.pdf)

Nederlands (NL) (125.78 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/nl/documents/overview/pravafenix-epar-summary-public_nl.pdf)

polski (PL) (161.3 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/pl/documents/overview/pravafenix-epar-summary-public_pl.pdf)

português (PT) (124.92 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/pt/documents/overview/pravafenix-epar-summary-public_pt.pdf)

română (RO) (150.92 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/ro/documents/overview/pravafenix-epar-summary-public_ro.pdf)

slovenčina (SK) (147.04 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sk/documents/overview/pravafenix-epar-summary-public_sk.pdf)

slovenščina (SL) (144.54 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sl/documents/overview/pravafenix-epar-summary-public_sl.pdf)

Suomi (FI) (121.63 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/fi/documents/overview/pravafenix-epar-summary-public_fi.pdf)

svenska (SV) (122.3 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sv/documents/overview/pravafenix-epar-summary-public_sv.pdf)

## Product information

Pravafenix : EPAR - Product Information

English (EN) (490.96 KB - PDF)

**First published:** 17/05/2011

**Last updated:** 17/01/2025

[View](/en/documents/product-information/pravafenix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-456)

български (BG) (513.03 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/bg/documents/product-information/pravafenix-epar-product-information_bg.pdf)

español (ES) (483.62 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/es/documents/product-information/pravafenix-epar-product-information_es.pdf)

čeština (CS) (579.98 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/cs/documents/product-information/pravafenix-epar-product-information_cs.pdf)

dansk (DA) (492.95 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/da/documents/product-information/pravafenix-epar-product-information_da.pdf)

Deutsch (DE) (469.05 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/de/documents/product-information/pravafenix-epar-product-information_de.pdf)

eesti keel (ET) (499.83 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/et/documents/product-information/pravafenix-epar-product-information_et.pdf)

ελληνικά (EL) (593.97 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/el/documents/product-information/pravafenix-epar-product-information_el.pdf)

français (FR) (505.32 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/fr/documents/product-information/pravafenix-epar-product-information_fr.pdf)

hrvatski (HR) (472.04 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/hr/documents/product-information/pravafenix-epar-product-information_hr.pdf)

íslenska (IS) (491.3 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/is/documents/product-information/pravafenix-epar-product-information_is.pdf)

italiano (IT) (616.38 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/it/documents/product-information/pravafenix-epar-product-information_it.pdf)

latviešu valoda (LV) (563.65 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/lv/documents/product-information/pravafenix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (469.11 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/lt/documents/product-information/pravafenix-epar-product-information_lt.pdf)

magyar (HU) (499.75 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/hu/documents/product-information/pravafenix-epar-product-information_hu.pdf)

Malti (MT) (639.1 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/mt/documents/product-information/pravafenix-epar-product-information_mt.pdf)

Nederlands (NL) (440.69 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/nl/documents/product-information/pravafenix-epar-product-information_nl.pdf)

norsk (NO) (438.74 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/no/documents/product-information/pravafenix-epar-product-information_no.pdf)

polski (PL) (562.37 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/pl/documents/product-information/pravafenix-epar-product-information_pl.pdf)

português (PT) (448.39 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/pt/documents/product-information/pravafenix-epar-product-information_pt.pdf)

română (RO) (474.49 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/ro/documents/product-information/pravafenix-epar-product-information_ro.pdf)

slovenčina (SK) (586.8 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sk/documents/product-information/pravafenix-epar-product-information_sk.pdf)

slovenščina (SL) (489.32 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sl/documents/product-information/pravafenix-epar-product-information_sl.pdf)

Suomi (FI) (434.68 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/fi/documents/product-information/pravafenix-epar-product-information_fi.pdf)

svenska (SV) (460.97 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

17/01/2025

[View](/sv/documents/product-information/pravafenix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0037 21/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pravafenix  : EPAR - All Authorised presentations

English (EN) (25.15 KB - PDF)

**First published:** 17/05/2011

**Last updated:** 29/08/2013

[View](/en/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-183)

български (BG) (51.32 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/bg/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.93 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/es/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.21 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/cs/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (21.32 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/da/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (21.32 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/de/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.74 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/et/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.85 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/el/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_el.pdf)

français (FR) (24.04 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/fr/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.44 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/hr/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.28 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/is/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.05 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/it/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.77 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/lv/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.33 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/lt/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.95 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/hu/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.27 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/mt/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.21 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/nl/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.11 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/no/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.84 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/pl/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.98 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/pt/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.95 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/ro/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.72 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/sk/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.04 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/sl/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21.24 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/fi/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.86 KB - PDF)

**First published:**

17/05/2011

**Last updated:**

29/08/2013

[View](/sv/documents/all-authorised-presentations/pravafenix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pravafenix Active substance

- fenofibrate
- pravastatin

International non-proprietary name (INN) or common name

- fenofibrate
- pravastatin

Therapeutic area (MeSH) Dyslipidemias Anatomical therapeutic chemical (ATC) code C10BA03

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Pravafenix is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the treatment of mixed hyperlipidaemia in adult patients at high cardiovascular risk to reduce triglycerides and increase HDL C when LDL C levels are adequately controlled while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen.

## Authorisation details

EMA product number EMEA/H/C/001243 Marketing authorisation holder

Laboratoires SMB S.A.

Rue de la Pastorale 26-28

Marketing authorisation issued 14/04/2011 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pravafenix  : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (200.66 KB - PDF)

**First published:** 29/08/2013

**Last updated:** 17/01/2025

[View](/en/documents/procedural-steps-after/pravafenix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pravafenix-H-C-001243-II-0037 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/569435/2024

English (EN) (633.14 KB - PDF)

**First published:** 17/01/2025

[View](/en/documents/variation-report/pravafenix-h-c-001243-ii-0037-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Pravafenix (II-37)

Adopted

Reference Number: EMA/CHMP/423595/2024

English (EN) (121.11 KB - PDF)

**First published:** 20/09/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pravafenix-ii-37_en.pdf)

Pravafenix-H-C-PSUSA-00001363-202304 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/CHMP/564966/2023

English (EN) (129.74 KB - PDF)

**First published:** 26/03/2024

[View](/en/documents/scientific-conclusion/pravafenix-h-c-psusa-00001363-202304-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Pravafenix  : EPAR - Public assessment report

Adopted

Reference Number: EMA/79515/2011

English (EN) (756.38 KB - PDF)

**First published:** 17/05/2011

**Last updated:** 17/05/2011

[View](/en/documents/assessment-report/pravafenix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pravafenix

Adopted

Reference Number: EMA/37551/2011

English (EN) (130.36 KB - PDF)

**First published:** 21/01/2011

**Last updated:** 21/01/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pravafenix_en.pdf)

#### News on Pravafenix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

#### More information on Pravafenix

- [A European, observational, three-year cohort comparative study on the safety of the fixed-dose combination pravastatin 40 mg/fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice (POSE) - post-authorisation study](https://catalogues.ema.europa.eu/study/38822)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/01/2025

## Share this page

[Back to top](#main-content)